insights_auto
为什么 GNLX 下跌了 3.57%?
深入探索chevron_right
GNLX:NASDAQ
Genelux Corp
US$2.43
arrow_downward
-3.57%(-0.090) 1 天
10月14日, GMT-4 12:36:44 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 GNLX 生成关键数据洞见…
开盘价
US$2.48
最高价
US$2.52
最低价
US$2.43
市值
1.10亿
平均成交量
24.34万
成交量
9.37万
52 周最高价
US$8.54
52 周最低价
US$2.29
每股收益
-US$0.87
Beta 版
0.59
流通股数
4524.50万
员工人数
26
开盘价
US$2.48
最高价
US$2.52
最低价
US$2.43
市值
1.10亿
平均成交量
24.34万
成交量
9.37万
52 周最高价
US$8.54
52 周最低价
US$2.29
每股收益
-US$0.87
Beta 版
0.59
流通股数
4524.50万
员工人数
26
新闻报道
来自网络来源和新闻合作伙伴
CoinDesk
·
6小时前
标普500期权成为该超流动交易所最热门的押注
Traders Union
·
13小时前
Ryan Detrick：遵循中期选举年后的市场规律，S&P 500 自 2026 年 3 月 30 日以来上涨约 18%
www.tmgm.com
·
19小时前
道琼斯工业平均指数回吐因财报带来的500点涨幅
Yellow.com
·
21小时前
标普500涨势能否延续，取决于AI指引？美股财报季拉开帷幕
资料
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Genelux Corp简介